Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 1/20 | 0.40 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.37 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.37 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.37 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.36 |
| ▸ | TRPA1 | O75762 | 5/20 | 0.36 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.35 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.34 |
| ▸ | CETP | P11597 | 1/20 | 0.34 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.34 |
| ▸ | TRPV3 | Q8NET8 | 1/20 | 0.34 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2348001 | 1.00 | DPP4 (0.40) | DPP4CHRM2CHRM1CHRM3ABCB1 | |
| SCHEMBL3717928 | 0.90 | DPP4 (0.39) | DPP4CHRM2CHRM1CHRM3ABCB1 | |
| SCHEMBL2351859 | 0.88 | FFAR2 (0.43) | DPP4ABCB1TRPA1MEN1KMT2A | |
| SCHEMBL2350570 | 0.84 | TRPA1 (0.47) | ABCB1TRPA1MEN1KMT2A | |
| SCHEMBL14563127 | 0.84 | TRPA1 (0.47) | ABCB1TRPA1MEN1KMT2A | |
| SCHEMBL14563128 | 0.84 | TRPA1 (0.47) | ABCB1TRPA1MEN1KMT2A | |
| SCHEMBL2583441 | 0.82 | DPP4 (0.38) | DPP4CHRM2CHRM1CHRM3ABCB1 | |
| SCHEMBL28528295 | 0.82 | RIPK1 (0.50) | ABCB1TRPA1RIPK1MEN1KMT2A | |
| SCHEMBL5149946 | 0.81 | ABCB1 (0.52) | ABCB1RIPK1MEN1KMT2ANR1H2 | |
| SCHEMBL475729 | 0.81 | ABCB1 (0.52) | ABCB1RIPK1MEN1KMT2ANR1H2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2125829-B1 | BICYCLIC OXOMORPHOLINE DERIVATIVE | EISAI R&D MAN CO LTD (JP) | 2013-01-16 | — | — | EP | disclosed |
| US-8008293-B2 | Bicyclic oxomorpholine derivative | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2011-08-30 | — | — | US | disclosed |
| US-7737141-B2 | such as -{4-{1-[(S)-1-(4-fluorophenyl)ethyl]-2-oxopiperidin-(3E)-ylidenemethyl}-2-methoxyphenyl}-5-methyl-1-(phosphonooxymethyl)-3H-imidazol-1-ium trifluoroacetate, which inhibit the synthesis of amyloid precursor proteins; treatment of Alzheimer's disease, Down syndrome or amyloidosis | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-06-15 | — | — | US | disclosed |
| US-20100113773-A1 | BICYCLIC OXOMORPHOLINE DERIVATIVE | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-05-06 | — | — | US | disclosed |
| EP-2048143-A1 | PRODRUG OF CINNAMIDE COMPOUND | Eisai R&D Management Co., Ltd. (JP) | 2009-04-15 | — | — | EP | disclosed |
| US-20090048213-A1 | Prodrug of cinnamide compound | EISAI R&D MANAGEMENT CO., LTD. | 2009-02-19 | — | — | US | disclosed |
| US-20080207900-A1 | TWO CYCLIC OXOMORPHORIN DERIVATIVES | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2008-08-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080207900-A1 | TWO CYCLIC OXOMORPHORIN DERIVATIVES | OPRM1, OPRK1, OPRD1 | DPP4 2646/4885CHRM2 171/4885CHRM1 98/4885 |
| US-20100113773-A1 | BICYCLIC OXOMORPHOLINE DERIVATIVE | OPRM1, OPRK1, OPRD1 | DPP4 2057/4885CHRM2 30/4885CHRM1 15/4885 |
| US-20090048213-A1 | Prodrug of cinnamide compound | BTK, CNKSR1, AKT1 | DPP4 1825/4885CHRM2 3067/4885CHRM1 2071/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.